Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 30.78M 26.89M 24.7M 23.03M 43.66M 2.93B 44.4M 297M 115M 1.44B 116M 113M 4.95B P/E 2026 *
-1.16x
P/E 2027 * -1.75x
Enterprise Value 30.78M 26.89M 24.7M 23.03M 43.66M 2.93B 44.4M 297M 115M 1.44B 116M 113M 4.95B EV / Sales 2026 *
-
EV / Sales 2027 * 2.38x
Free-Float
97.65%
Yield 2026 *
-
Yield 2027 * -
06-03 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
06-01 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
06-01 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
05-30 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
05-30 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
05-09 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
05-06 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
04-22 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
04-22 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
04-06 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
03-31 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
02-17 CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 CI
02-14 Actinium Pharmaceuticals, Inc. Announces Executive Changes, Effective as of February 27, 2026 CI
1 day+0.12%
1 week+3.26%
Current month+0.10%
1 month-19.59%
3 months+0.06%
6 months-28.39%
Current year-27.87%
1 week 0.95
Extreme 0.9501
1.01
1 month 0.94
Extreme 0.94
1.18
Current year 0.94
Extreme 0.94
1.53
1 year 0.94
Extreme 0.94
1.89
3 years 0.94
Extreme 0.94
10.24
5 years 0.94
Extreme 0.94
15.12
10 years 0.94
Extreme 0.94
64.5
Manager TitleAgeSince
Chief Executive Officer 62 09/06/2017
Chief Tech/Sci/R&D Officer - 01/06/2026
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 71 01/01/2008
Chairman 62 01/10/2013
Director/Board Member 68 08/11/2013
Date Insider Type Main position Quantity % Market Cap.
18/08/25Tax

Chief Executive Officer

120,900 0.3876%
31/03/25Issuer sale

Director

182,484 0.5850%
31/03/25Issuer sale

Director

184,984 0.5930%
Change 5-day change 1-year change 3-year change Capi.($)
+0.12%+3.26%-31.40%-86.78% 30.78M
-0.97%+4.18%+77.50%+133.89% 58.73B
-3.12%+3.48%+72.79%+94.67% 53.92B
+3.86%+8.38%-9.90%-9.62% 24.67B
+4.30%+6.82%+13.60%+428.91% 24.19B
+4.74%+13.68%+45.58%-1.42% 18.8B
-0.72%+9.43%+44.16%-28.17% 17.61B
+2.57%+16.74%+171.12%+355.99% 16.25B
+3.50%+4.92%+26.07%+192.26% 14.04B
+6.72%+19.38%+42.82% - 13.9B
Average +2.10%+7.67%+45.23%+119.97% 24.21B
Weighted average by Cap. +0.97%+7.21%+57.56%+136.11%

Financials

2026 *2027 *
Net sales - 12.93M 11.3M 10.37M 9.67M 18.34M 1.23B 18.65M 125M 48.4M 604M 48.54M 47.48M 2.08B
Net income -28.5M -24.9M -22.87M -21.33M -40.43M -2.71B -41.11M -275M -107M -1.33B -107M -105M -4.59B -23.27M -20.33M -18.67M -17.41M -33.01M -2.22B -33.56M -225M -87.12M -1.09B -87.37M -85.47M -3.74B
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
25
Date Price Change Volume
02/07/26 $0.9810 +0.12% 32,878
01/07/26 $0.9798 -0.02% 93,296
30/06/26 $0.9800 -1.01% 143,978
29/06/26 $0.9900 0.00% 124,570
26/06/26 $0.9900 +4.21% 126,337
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.9810USD
Average target price
5.000USD
Spread / Average Target
+409.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock